Discovery of a potent dual EGFR/HER-2 inhibitor L-2 (selatinib) for the treatment of cancer

European Journal of Medicinal Chemistry

Volumn 69, Issue , 2013, Pages 833-841

  Zhang, Long ^a   Fan, Chuanwen ^a   Guo, Zongru ^b   Li, Ying ^c   Zhao, Shuyong ^a   Yang, Shaobo ^a   Yang, Yingying ^a   Zhu, Jianrong ^c   Lin, Dong ^a  

^a Qilu Pharmaceutical Co Ltd   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c LANZHOU UNIVERSITY   (China)

Author keywords

EGFR; HER 2; Lapatinib analogs; NCI N87; Selatinib; SK OV 3

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; LAPATINIB; SELATINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL;

EGFR; HER-2; LAPATINIB ANALOGS; NCI-N87; SELATINIB; SK-OV-3;

ANILINE COMPOUNDS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR STRUCTURE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; QUINAZOLINES; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84885077274     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.09.032     Document Type: Article

References (25)

1. J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 103 2000 211 225
2. Y. Yarden, and M.X. Sliwkowski Untangling the ErbB signalling network Nat. Rev. Mol. Cell Biol. 2 2001 127 137 (Pubitemid 33674041)
3. M.A. Olayioye, R.M. Neve, and H.A. Lane The ErbB signaling network: receptor heterodimerization in development and cancer EMBO J. 19 2000 3159 3167 (Pubitemid 30428195)
4. R.S. Herbst, and C.J. Langer Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers Semin. Oncol. 29 2002 27 36 (Pubitemid 34226516)
5. M.G. Kris, R.B. Natale, and R.S. Herbst Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 290 2003 2149 2158 (Pubitemid 37432975)
6. ®) tablets The Oncologist 10 2005 461 466 (Pubitemid 41266326)
7. S. Maheswaran, L.V. Sequist, and S. Nagrath Detection of mutations in EGFR in circulating lung-cancer cells N. Engl. J. Med. 359 2008 366 377
8. M. Ranson, L.A. Hammond, and D. Ferry ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial J. Clin. Oncol. 20 2002 2240 2250 (Pubitemid 34441651)
9. F. Ciardiello, and G. Tortora A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor Clin. Cancer Res. 7 2001 2958 2970 (Pubitemid 32963812)
10. S.R.D. Johnston, and A. Leary Lapatinib: a novel EGFR/HER-2 tyrosine kinase inhibitor for cancer Drugs Today 42 2006 441
11. N.L. Spector, K.L. Blackwell, and J. Hurley EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response J. Clin. Oncol. 24 2006 502
12. H.A. Burris III, H.I. Hurwitz, and E.C. Dees Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas J. Clin. Oncol. 23 2005 5305 5313 (Pubitemid 46206984)
13. A.K. Bence, E.B. Anderson, and M.A. Halepota Phase I pharmacokinetic studies evaluating single and multiple doses of oral GW572016, a dual EGFR-ErbB2 inhibitor, in healthy subjects Invest New Drugs 23 2005 39 49 (Pubitemid 39505950)
14. C.A. Lipinski, F. Lombardo, and B.W. Dominy Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 46 2001 3 26 (Pubitemid 33653411)
15. N.R. Budha, A. Frymoyer, and G.S. Smelick Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin. Pharmacol. Ther. 92 2012 203 213
16. J. Stamos, M.X. Sliwkowski, and C. Eigenbrot Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor J. Biol. Chem. 277 2002 46265 46272 (Pubitemid 35417619)
17. C.H. Yun, T.J. Boggon, and Y. Li Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227 (Pubitemid 46349842)
18. M. Scaltriti, C. Verma, and M. Guzman Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity Oncogene 28 2009 803 814
19. E.R. Wood, A.T. Truesdale, and O.B. McDonald A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells Cancer Res. 64 2004 6652
20. J.M. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat. Rev. Cancer 9 2009 28 39
21. P.J. Medina, and S. Goodin Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases Clin. Ther. 30 2008 1426
22. ®, GW572016) in an expanded panel of human normal and tumour cell lines Cell Prolif. 40 2007 580 594 (Pubitemid 47063294)
23. T.E. Kim, and J.R. Murren Lapatinib ditosylate GlaxoSmithKline IDrugs 6 2003 886 893 (Pubitemid 37168205)
24. L. Zhong, X.N. Guo, and X.H. Zhang Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening Biochim. Biophys. Acta 1722 2005 254 261 (Pubitemid 40354164)
25. E. Baka, and K. Takács-Novák Study on standardization of shake-flask solubility determination method Eur. J. Pharm. Sci. 32 2007 S23 S24